METiS Therapeutics, a biopharmaceutical company based in Cambridge, Massachusetts, has secured USD 100 million in a Series C financing round. The round was led by CICC Capital, with additional investment from China Taiping Insurance. This latest funding round brings the total capital raised by the Sino-US firm to USD 300 million.
Nurtured by XtalPi, METiS focuses on the development of an AI-driven drug and delivery system. The company plans to use the proceeds to strengthen the construction of its AI-enhanced drug delivery platform and to advance the development of its in-house pipeline.- Flcube.com
